Glaxo Says Compound in Wine May Fight Aging

New York Times report on GlaxoSmithKline's announced $720 million cash acquisition of Sirtris Pharmaceuticals, at $22.50 per share, an 84% premium over Sirtris's prior closing price; quotes GSK R&D head Moncef Slaoui describing Sirtris's science as 'potentially transformative.' Byline/date/headline corroborated independently against the Nature Biotechnology news item ('GSK moves on Sirtris,' 2 June 2008) and C&EN coverage (28 April 2008), which report identical acquisition terms; the NYT page itself sits behind a metered paywall and was not directly re-fetchable by the automated browser in this authoring session, so this citation rests on cross-corroborated secondary reporting of the same primary announcement rather than a direct fetch of nytimes.com.